분야
pptxBackground
Methods
Results
Discussion
Conclusions
Clinical application
Take home messages
Continue to threaten global health. (Covid-19)
Older age, current smoking, or underlying clinical conditions such as cardiovascular disease, diabetes, obesity, and cancer : high risk for severe Covid-19 and associated adverse outcomes.
Twice as likely to have progression to severe Covid-19 and five times as likely to die from Covid-19 as patients without those conditions.
A need exists for safe and effective oral Covid-19 treatments : reducing hospitalization, and death. (Lack of resources)
Nirmatrelvir : severe acute respiratory syndrome coronavirus 2 main protease (Mpro) inhibitor with potent pan–human-coronavirus activity in vitro.
Ritonavir low dose 100mg (CYP3A inhibitor) : Enhancing nirmatrelvir pharmacokinetics (approximately five to six times in vitro 90% effective concentration of nirmatrelvir)
